ICU Medical Reports Q1 2026 Earnings: EPS Beats Estimates Despite Revenue Miss
ICU Medical, Inc. (ICUI) held its first-quarter 2026 earnings conference call on May 7, 2026, to discuss financial performance and strategic updates. The company reported earnings per share (EPS) of $1.97, surpassing analyst expectations by $0.13. However, total revenue came in at $525.77 million, representing a 12.30% year-over-year decline and missing estimates by $6.93 million. Key executives, including CEO Vivek Jain and CFO Brian Bonnell, participated in the call alongside analysts from major firms such as Raymond James, KeyBanc, and Jefferies. The session included prepared remarks regarding the company's operational results and forward-looking statements, with management emphasizing that future projections are based on current assumptions and subject to market risks. Investors were directed to the company’s SEC filings for detailed risk information. The mixed financial results highlight a divergence between profitability metrics and top-line growth, drawing attention from institutional investors and market analysts monitoring the medical device sector's performance in early 2026.
Wire timeline
ICU Medical Reports Q1 2026 Earnings: EPS Beats Estimates Despite Revenue Miss
ICU Medical, Inc. (ICUI) held its first-quarter 2026 earnings conference call on May 7, 2026, to discuss financial performance and strategic updates. The company reported earnings per share (EPS) of $1.97, surpassing analyst expectations by $0.13. However, total revenue came in at $525.77 million, representing a 12.30% year-over-year decline and missing estimates by $6.93 million. Key executives, including CEO Vivek Jain and CFO Brian Bonnell, participated in the call alongside analysts from major firms such as Raymond James, KeyBanc, and Jefferies. The session included prepared remarks regarding the company's operational results and forward-looking statements, with management emphasizing that future projections are based on current assumptions and subject to market risks. Investors were directed to the company’s SEC filings for detailed risk information. The mixed financial results highlight a divergence between profitability metrics and top-line growth, drawing attention from institutional investors and market analysts monitoring the medical device sector's performance in early 2026.
All Articles on Seeking Alpha